GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 agonist medication can help improve insulin secretion in people with cystic fibrosis who have abnormal glucose tolerance or diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) study

Participants 30 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2021-07 · est. completion 2028-06

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT04731272 ↗

Description as written by the study sponsor.

Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD development. In this study, we hypothesize that weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide will improve defective early-phase insulin secretion and improve glucose tolerance during a mixed-meal tolerance test.

Treatments tested

Dulaglutide 0.75Mg/0.5Ml Inj Pen Drug

Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.

Main thing measured	Early-phase insulin secretion
Sponsor	University of Pennsylvania
Conditions studied	Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04731272 ↗